13.1 Preconception Planning & Comprehensive Contraception Management

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

13.1 Preconception Planning & Comprehensive Contraception Management

Key Takeaways Explain This Topic AI

The USPSTF issues a Grade A recommendation for daily folic acid supplementation (0.4–0.8 mg [400–800 mcg]) for all persons planning or capable of pregnancy; high-dose folic acid (4.0 mg [4,000 mcg] daily) is indicated starting at least 1–3 months preconception for individuals with a prior neural tube defect pregnancy, antiepileptic drug use (valproate, carbamazepine), or pregestational diabetes.

Preconception glycemic optimization targets an HbA1c <6.5% to dramatically lower the risk of congenital malformations—most notably caudal regression syndrome (sacral agenesis) and conotruncal cardiac defects; chronic hypertension requires transitioning from ACE inhibitors, ARBs, and mineralocorticoid antagonists to labetalol, nifedipine, or methyldopa.

Under the CDC US Medical Eligibility Criteria (US MEC), Category 4 represents an unacceptable health risk (absolute contraindication); combined hormonal contraceptives (CHCs) are strictly Category 4 in migraine with aura, age ≥35 smoking ≥15 cigarettes/day, uncontrolled severe hypertension (SBP ≥160 or DBP ≥100 mm Hg), acute/prior DVT/PE, thrombogenic mutations, active breast cancer, ischemic heart disease, severe cirrhosis, and postpartum <21 days.

Tier 1 Long-Acting Reversible Contraceptives (LARCs) have failure rates <1% and include 52 mg levonorgestrel IUDs (approved up to 8 years), copper T380A IUD (10–12 years), and etonogestrel subdermal implants (Nexplanon, up to 5 years); unscheduled irregular bleeding is the most common side effect of Nexplanon requiring proactive anticipatory counseling.

Emergency contraception options include the copper IUD (most effective, >99%, within 5 days regardless of BMI), oral ulipristal acetate 30 mg (effective up to 5 days, superior in BMI ≥30 kg/m², but mandates a 5-day pause before starting routine hormonal contraception), and oral levonorgestrel 1.5 mg (effective within 72 hours, OTC, but reduced efficacy in BMI ≥25–30 kg/m²).

Last updated: September 2026

Preconception Optimization & Risk Mitigation

Preconception care represents one of the highest-yield preventive interventions in family medicine. The goal of preconception counseling is to identify, mitigate, and manage biomedical, behavioral, and environmental risks to a patient's health and pregnancy outcomes before conception occurs. Because approximately 45% of pregnancies in the United States remain unintended, and organogenesis begins during the third to eighth embryonic weeks—often before a patient recognizes pregnancy—preconception risk assessment must be integrated routinely into primary care encounters for all reproductive-capable individuals.

Folic Acid Supplementation Strategies

Neural tube closure occurs between 21 and 28 days post-conception. Neural tube defects (NTDs), including anencephaly and spina bifida (myelomeningocele), result from failure of embryonic neural tube fusion. Folic acid (pteroylglutamic acid) is essential for one-carbon metabolism and nucleotide synthesis during rapid cellular division.

Standard-Risk Supplementation (USPSTF Grade A) : All individuals planning or capable of pregnancy should consume 0.4 to 0.8 mg (400 to 800 mcg) of oral folic acid daily . Supplementation should ideally begin at least 1 month prior to conception and continue through at least the first 12 weeks (first trimester) of gestation, though continuing through delivery is standard prenatal practice.

High-Risk Supplementation (4.0 mg [4,000 mcg] Daily) : A ten-fold higher dose of 4.0 mg daily is indicated for high-risk clinical populations. High-dose supplementation must be initiated at least 1 to 3 months prior to conception and maintained through the first 12 weeks of gestation, after which it can be reduced to 0.4 to 0.8 mg daily. Specific high-risk criteria include:

• Personal history of a prior pregnancy affected by a neural tube defect
• Either prospective biological parent having a neural tube defect

Concurrent therapy with antiepileptic drugs that impair folate metabolism (specifically valproic acid and carbamazepine )

• Pregestational diabetes mellitus (Type 1 or Type 2)
• Malabsorption syndromes (active inflammatory bowel disease, celiac disease, prior bariatric bypass surgery)
• Sickle cell disease and other chronic hemolytic anemias
• Chronic Disease Optimization Prior to Conception
• 1. Pregestational Diabetes Mellitus (Type 1 & Type 2)

Hyperglycemia during organogenesis exerts direct teratogenic effects through reactive oxygen species generation, membrane lipid peroxidation, and cellular apoptosis in embryonic tissues. The risk of major congenital anomalies is directly proportional to periconceptional glycemic control:

Glycemic Target : The preconception goal is an HbA1c <6.5% without frequent severe hypoglycemia. Every 1% reduction in HbA1c toward normal significantly decreases malformation rates.

Associated Malformations : Uncontrolled periconceptional maternal hyperglycemia markedly elevates the risk of complex cardiac malformations (ventricular septal defects, transposition of the great arteries, coarctation of the aorta) and central nervous system defects. Most characteristically, it is associated with caudal regression syndrome (sacral agenesis) —an exceedingly rare malformation occurring 200 times more frequently in pregnancies complicated by uncontrolled pregestational diabetes.

Long-Term Complication Screening : Assess for diabetic retinopathy (dilated funduscopic exam), nephropathy (serum creatinine, urine albumin-to-creatinine ratio), neuropathy, and cardiovascular disease before conception. Discontinue teratogenic non-insulin therapies (such as SGLT2 inhibitors and GLP-1 receptor agonists, for which human safety data remain limited) and transition to insulin as the gold standard for glycemic control in pregnancy.

2. Chronic Hypertension & Teratogenic Antihypertensive Transition

Chronic hypertension (blood pressure ≥ 130 / 80 \ge 130/80 ≥ 130/80 mm Hg prior to pregnancy or before 20 weeks gestation) increases the risk of superimposed preeclampsia, placental abruption, fetal growth restriction (FGR), and preterm delivery.

Discontinuation of Teratogens : Inhibitors of the renin-angiotensin-aldosterone system (RAAS)—including ACE inhibitors (e.g., lisinopril) , Angiotensin Receptor Blockers (ARBs, e.g., losartan) , and direct renin inhibitors (aliskiren)—are potent fetotoxins. Exposure during the second and third trimesters causes fetal renal dysgenesis, profound oligohydramnios, pulmonary hypoplasia, skull ossification defects, limb contractures, and neonatal anuria. Mineralocorticoid receptor antagonists (spironolactone) exert anti-androgenic effects that disrupt male external genitalia development. All RAAS inhibitors and spironolactone must be discontinued prior to conception.

First-Line Pregnancy-Safe Antihypertensives :

Labetalol : Combined alpha-1 and non-selective beta-blocker. First-line oral dosing starts at 100 mg twice daily, titrating up to 800 mg twice or three times daily (maximum 2,400 mg/day). Avoid in patients with active reactive airway disease or severe bradycardia.

Nifedipine (Extended-Release) : Dihydropyridine calcium channel blocker. Starting dose 30 mg orally once daily, titrating up to 90–120 mg daily. Rapid-acting sublingual nifedipine is contraindicated due to precipitous hypotension and fetal hypoperfusion.

Methyldopa : Central alpha-2 adrenergic agonist. Historic first-line agent with an extensive long-term pediatric safety track record, though limited by maternal somnolence, depression, and hepatic transaminitis. Dosing: 250 mg twice or three times daily up to 3,000 mg/day.

Blood Pressure Goals : In accordance with the landmark CHAP trial, the recommended blood pressure target in chronic hypertension during pregnancy is systolic 110–135 mm Hg and diastolic 70–85 mm Hg to mitigate preeclampsia and maternal end-organ complications while preserving uteroplacental perfusion.

3. Teratogenic Medication Review & Discontinuation Timelines

Medication / Class Teratogenic Mechanism & Congenital Phenotype Recommended Management & Preconception Washout

ACE Inhibitors & ARBs Fetal renal tubular dysgenesis, oligohydramnios sequence, pulmonary hypoplasia, calvarial hypoplasia Discontinue prior to conception; transition to labetalol, extended-release nifedipine, or methyldopa

Statins (HMG-CoA Reductase Inhibitors) Disruption of cholesterol biosynthesis essential for embryonic cell membrane and steroidogenesis Discontinue prior to attempting conception (hold throughout pregnancy and lactation)

Methotrexate Dihydrofolate reductase inhibition; "methotrexate embryopathy" (craniosynostosis, micrognathia, skeletal limb hypoplasia) Discontinue at least 3 months prior to conception; prescribe high-dose folic acid (4.0 mg daily)

Isotretinoin (Retinoids) Severe retinoic acid embryopathy (craniofacial anomalies, microtia/anotia, thymic aplasia, conotruncal heart defects) Discontinue at least 1 month prior ; mandatory two negative pregnancy tests and two forms of contraception (iPLEDGE program)

Valproic Acid Folate antagonism and histone deacetylase inhibition; neural tube defects (1–2%), cleft lip/palate, developmental delay Transition to safer antiepileptic (e.g., lamotrigine, levetiracetam) prior to conception; if unavoidable, use lowest dose with 4.0 mg folate

Warfarin Vitamin K epoxide reductase inhibition; "warfarin embryopathy" (nasal hypoplasia, stippled epiphyses, microcephaly) Transition to low-molecular-weight heparin (LMWH, enoxaparin) prior to conception or immediately upon pregnancy confirmation

Preconception Immunizations & Infectious Disease Screening

Live Attenuated Vaccines (MMR and Varicella) : Live vaccines pose a theoretical risk of viral transmission to the fetus and are strictly contraindicated during pregnancy . Clinicians must assess immunity (serologic titers or documented history) preconceptionally. If non-immune, administer the vaccine series and counsel the patient to avoid conception for at least 28 days (4 weeks) following vaccination.

Inactivated Vaccines : Inactivated influenza vaccine (any trimester) and COVID-19 mRNA vaccines (any trimester) are strongly recommended to prevent severe maternal morbidity and respiratory failure.

Tdap Vaccine : Administered during each pregnancy between 27 and 36 weeks of gestation (regardless of prior immunization status) to maximize transplacental passive transfer of maternal anti-pertussis antibodies to the neonate.

Infectious Screening : Serologic screening for HIV, Syphilis (RPR/VDRL), Hepatitis B surface antigen (HBsAg), Rubella IgG, and Varicella IgG. Screen for Chlamydia trachomatis and Neisseria gonorrhoeae in all women < 25 <25 < 25 years of age and older individuals with clinical risk factors.

CDC US Medical Eligibility Criteria for Contraceptive Use (US MEC)

The Centers for Disease Control and Prevention (CDC) publishes the US Medical Eligibility Criteria for Contraceptive Use (US MEC) , which provides evidence-based guidance on the safety of contraceptive methods in the presence of specific medical conditions. The US MEC categorizes safety into four distinct tiers:

The US MEC Numerical Classification System

Category 1 : A condition for which there is no restriction for the use of the contraceptive method. (Example: Levonorgestrel IUD in a patient with well-controlled hypertension).

Category 2 : A condition where the advantages of using the method generally outweigh the theoretical or proven risks . The method can be used with routine clinical follow-up. (Example: Combined oral contraceptives in an uncomplicated, controlled diabetic aged < 35 <35 < 35 ).

Category 3 : A condition where the theoretical or proven risks usually outweigh the advantages of using the method. The method is NOT recommended unless other more appropriate methods are unavailable or unacceptable. (Example: Combined oral contraceptives in a woman aged ≥ 35 \ge 35 ≥ 35 who smokes < 15 <15 < 15 cigarettes/day).

Category 4 : A condition that represents an unacceptable health risk if the contraceptive method is used ( absolute contraindication ). (Example: Combined oral contraceptives in a patient with migraine with aura).

Contraceptive Efficacy Tiers & Method Characteristics

Contraceptive methods are grouped into three primary clinical tiers based on failure rates in typical real-world use: CONTRACEPTIVE EFFICACY TIERS

• ┌────────────────────────────────────────────────────────────────────────────────────────┐
• │ TIER 1: Long-Acting Reversible Contraception (LARC) & Sterilization (<1% Failure Rate) │
• │ • Subdermal Etonogestrel Implant (Nexplanon: 0.05% failure rate, approved 3-5 years) │
• │ • Levonorgestrel IUDs (52 mg Mirena/Liletta [8 yrs], 19.5 mg [5 yrs], 13.5 mg [3 yrs]) │
• │ • Copper T380A IUD (ParaGard: non-hormonal, 10-12 years, emergency contraception) │
• │ • Female Tubal Occlusion / Male Vasectomy (permanent sterilization) │
• └───────────────────────────────────────────┬────────────────────────────────────────────┘
• │
• ┌───────────────────────────────────────────┴────────────────────────────────────────────┐
• │ TIER 2: Hormonal Injections, Pills, Patches & Rings (4–7% Typical Failure Rate) │
• │ • Depot Medroxyprogesterone Acetate (DMPA: 150 mg IM / 104 mg SC q13wk, BMD warning) │
• │ • Combined Oral Contraceptive Pills (COCs: daily, 21/7 or extended cycle) │
• │ • Transdermal Patch (EE/Norelgestromin: weekly, VTE risk in BMI ≥30 kg/m²) │
• │ • Vaginal Rings (NuvaRing: monthly; Annovera: reusable for 1 year) │
• │ • Progestin-Only Pills (POPs: Norethindrone strict 3h window; Drospirenone 24h window) │
• └───────────────────────────────────────────┬────────────────────────────────────────────┘
• │
• ┌───────────────────────────────────────────┴────────────────────────────────────────────┐
• │ TIER 3: Barrier, Behavioral & Coital Methods (13–24% Typical Failure Rate) │
• │ • Male Condoms (13% typical failure, provides STI protection) │
• │ • Female Condoms, Diaphragms with Spermicide, Cervical Caps (17–21% failure) │
• │ • Fertility Awareness-Based Methods, Withdrawal (Coitus Interruptus), Sponge (18–24%) │
• └────────────────────────────────────────────────────────────────────────────────────────┘
• Tier 1: Long-Acting Reversible Contraceptives (LARC)

LARCs represent the most effective reversible methods because their efficacy is independent of patient adherence:

Subdermal Etonogestrel Implant (Nexplanon) :

Design : Single 4-cm rod containing 68 mg of etonogestrel placed subdermally in the non-dominant inner upper arm. Approved for 3 years, with clinical trial evidence demonstrating efficacy through 5 years .

Mechanism : Ovulation suppression via pituitary LH inhibition, thickening of cervical mucus, and endometrial thinning. Highest efficacy of any reversible contraceptive ( < 0.05 % <0.05\% < 0.05% failure rate).

Clinical Side Effects & Counseling : Unscheduled, irregular, unpredictable uterine bleeding is the most common adverse effect and the leading reason for premature discontinuation. Amenorrhea develops in approximately 20% of users. Bleeding episodes can be managed with a 5- to 7-day course of oral NSAIDs (e.g., ibuprofen 600–800 mg three times daily), a 1- to 3-month trial of combined oral contraceptives, or oral tranexamic acid.

Levonorgestrel Intrauterine Devices (LNG-IUD) :

52 mg Formulations (Mirena, Liletta) : Initial release ~20 mcg/day; approved for up to 8 years . Causes marked local endometrial decidualization and glandular atrophy, while thickening cervical mucus. Significantly reduces menstrual blood loss (by up to 90%) and dysmenorrhea; amenorrhea occurs in 20% of patients at 1 year and 50% at 5 years. First-line therapy for idiopathic heavy menstrual bleeding (menorrhagia).

19.5 mg (Kyleena) : Approved for 5 years ; intermediate hormone dose and smaller frame.

13.5 mg (Skyla) : Approved for 3 years ; lowest hormone dose and smaller frame, tailored for nulliparous patients with smaller uterine cavities.

Copper T380A Intrauterine Device (ParaGard) :

Design : Completely non-hormonal, polyethylene T-frame wrapped with 380 mm² of copper wire. FDA-approved for 10 years , with high efficacy demonstrated through 12 years .

Mechanism : Continuous release of copper ions creates a sterile, cytotoxic foreign body inflammatory reaction in the endometrium and uterine fluid, which is toxic to spermatozoa and oocytes, preventing fertilization.

Clinical Side Effects : Frequently increases menstrual volume and crampy dysmenorrhea, particularly during the first 3 to 6 cycles. Managed with pre-emptive scheduled NSAIDs during menses. Highly preferred in patients who have contraindications to exogenous hormones or desire non-hormonal contraception.

Tier 2: Short-Acting Hormonal Contraceptives

Combined Hormonal Contraceptives (CHCs: Pills, Patch, Ring) :

Mechanism : Ethinyl estradiol (EE) suppresses FSH secretion (inhibiting follicular recruitment), while the progestin component suppresses the mid-cycle LH surge (inhibiting ovulation) and thickens cervical mucus.

Transdermal Patch (Xulane, Twirla) : Applied once weekly for 3 consecutive weeks, followed by 1 patch-free week. Generates higher steady-state systemic estrogen concentrations than standard 30-mcg COCs. Efficacy is significantly decreased and the risk of venous thromboembolism is increased in individuals with a BMI ≥ 30 \ge 30 ≥ 30 kg/m² or body weight ≥ 90 \ge 90 ≥ 90 kg.

Vaginal Rings : NuvaRing (etonogestrel/EE: worn intravaginally for 3 weeks, removed for 1 week); Annovera (segesterone acetate/EE: reusable ring washed and reinserted monthly for 1 full year).

Progestin-Only Pills (POPs) :

Norethindrone (0.35 mg, "Mini-Pill") : Does NOT reliably suppress ovulation (ovulation is inhibited in only ~50% of cycles); works primarily by thickening cervical mucus and thinning the endometrium. Due to a short plasma half-life, the cervical mucus effect wanes after 22 hours. Must be taken at the exact same time every day within a strict 3-hour window . If a pill is missed by > 3 >3 > 3 hours , the patient must take the missed pill immediately, continue daily dosing, and use backup barrier contraception for at least 48 hours .

Drospirenone (4 mg, Slynd) : 24 active pills and 4 inert pills. Reliably suppresses ovulation. Features a 24-hour missed-pill window , offering superior forgiving pharmacokinetics compared to norethindrone. Drospirenone is a spironolactone analogue with mild anti-mineralocorticoid activity; serum potassium monitoring is necessary only in patients with renal impairment, hepatic dysfunction, or concurrent potassium-sparing medication use.

Depot Medroxyprogesterone Acetate (DMPA, Depo-Provera) :

Dosing : 150 mg intramuscularly or 104 mg subcutaneously every 13 weeks (grace period up to 15 weeks without requiring exclusion of pregnancy).

Mechanism : High-dose progestin reliably blocks pituitary gonadotropin secretion, suppressing follicular maturation and ovulation.

Clinical Adverse Effects & Boxed Warnings :

Bone Mineral Density (BMD) Loss : Carries an FDA boxed warning regarding reversible reduction in bone mineral density. Bone loss stabilizes over time, and BMD substantially recovers following discontinuation. Routine surveillance with DEXA scans is NOT recommended by ACOG or the CDC, and therapy should not be arbitrarily restricted to 2 years if other methods are unsuitable.

Delayed Return to Fertility : Following cessation of DMPA, return to regular ovulatory cycles is delayed, averaging 9 to 18 months (median 10 months). DMPA is not ideal for patients desiring pregnancy within the subsequent 1 to 2 years.

Weight Gain : Average weight gain of 2 to 5 kg over 1 to 2 years, primarily in adolescents and overweight individuals.

Amenorrhea : Progressive amenorrhea develops in 50% of users by 1 year and 70% by 2 years.

Absolute Contraindications to Estrogen-Containing Contraceptives (US MEC 4)

Because ethinyl estradiol enhances hepatic synthesis of coagulation factors (factors II, VII, VIII, X, and fibrinogen) and decreases antithrombin III, combined hormonal contraceptives (COCs, patch, ring) increase the risk of venous thromboembolism and arterial thrombosis. Estrogen-containing contraceptives are strictly US MEC Category 4 (Unacceptable Health Risk) in the following clinical scenarios:

Master US MEC Category 4 Matrix for Combined Hormonal Contraceptives

Clinical Condition Underlying Pathophysiology & Risk Appropriate Alternative Contraception

Migraine with Aura (at any age) Profoundly elevates the risk of ischemic stroke due to cortical spreading depression, oligemia, and estrogenic hypercoagulability Progestin-only methods (LNG-IUD, Nexplanon, POPs, DMPA) or Copper IUD (all MEC 1 or 2)

Age ≥ 35 \ge 35 ≥ 35 and Smoking ≥ 15 \ge 15 ≥ 15 Cigarettes/Day Synergistic, exponential acceleration of arterial thrombosis, acute myocardial infarction, and stroke Copper IUD, LNG-IUD, Nexplanon, POPs (all MEC 1); DMPA (MEC 2)

Uncontrolled Severe Hypertension (SBP ≥ 160 \ge 160 ≥ 160 or DBP ≥ 100 \ge 100 ≥ 100 mm Hg) Precipitates acute hemorrhagic stroke, hypertensive encephalopathy, and cardiovascular collapse Copper IUD, LNG-IUD, Nexplanon, POPs (all MEC 1 or 2)

Current or Personal History of DVT or PE High recurrence rate of venous thromboembolism due to hypercoagulable state Copper IUD (MEC 1), LNG-IUD (MEC 2), Nexplanon/POPs (MEC 2)

Known Thrombogenic Mutations (e.g., Factor V Leiden, Prothrombin 20210A, Protein C/S deficiency) Extreme baseline thrombotic predisposition; estrogen triggers unprovoked VTE Copper IUD (MEC 1), LNG-IUD (MEC 2), Nexplanon/POPs (MEC 2)

Current or Personal History of Breast Cancer Estrogen and progestin stimulate tumor proliferation in hormone-receptor-positive breast cancers Copper IUD is the ONLY MEC 1 method. (All hormonal methods, including LNG-IUD, are MEC 4 for current cancer, MEC 3 for past cancer)

Acute Ischemic Heart Disease or Stroke Estrogen exacerbates arterial endothelial inflammation and occlusive thrombosis Copper IUD (MEC 1), LNG-IUD (MEC 2/3)

Severe Decompensated Cirrhosis or Hepatic Adenoma Impaired hepatic steroid metabolism; estrogen stimulates hepatocellular adenoma growth and rupture Copper IUD (MEC 1), LNG-IUD (MEC 2)

Postpartum < 21 <21 < 21 Days (Non-Breastfeeding or Breastfeeding) Early postpartum period is a state of extreme physiologic hypercoagulability Progestin-only methods (MEC 1/2); Copper IUD (MEC 1 if placed within 10 min of placenta or defer to 4 weeks)

Diabetes with End-Organ Damage (Nephropathy, retinopathy, neuropathy, or duration > 20 >20 > 20 years) Accelerates microvascular and macrovascular thrombosis Copper IUD (MEC 1), LNG-IUD (MEC 2), Nexplanon (MEC 2)

Exam Distinction : Migraine without aura in patients < 35 <35 < 35 years is US MEC Category 2 (advantages outweigh risks). Migraine without aura in patients ≥ 35 \ge 35 ≥ 35 years is US MEC Category 3 for continuation and Category 3/4 for initiation.

Emergency Contraception (EC): Protocols & Clinical Pharmacology

Emergency contraception provides an opportunity to prevent unintended pregnancy following unprotected intercourse, sexual assault, or contraceptive failure (e.g., condom rupture, missed oral pills). There are three primary emergency contraception modalities: EMERGENCY CONTRACEPTION MODALITIES

• ┌────────────────────────────────────────────────────────────────────────────────────────┐
• │ 1. COPPER T380A IUD (ParaGard) │
• │ • Timing: Insert within 120 hours (5 days) of unprotected coitus │
• │ • Efficacy: >99.9% effective (<0.1% failure rate) — Gold Standard │
• │ • BMI Impact: Unaffected by overweight or obesity (equally effective across all BMIs) │
• │ • Mechanism: Direct spermicidal and ovicidal inflammatory endometrial effect │
• │ • Benefit: Provides immediate, ongoing Tier 1 contraception for 10–12 years │
• └────────────────────────────────────────────────────────────────────────────────────────┘
• │
• ┌────────────────────────────────┴────────────────────────────────┐
• ▼ ▼
• ┌─────────────────────────────────────────┐ ┌─────────────────────────────────────────┐
• │ 2. ORAL ULIPRISTAL ACETATE (Ella, 30mg) │ │ 3. ORAL LEVONORGESTREL (Plan B, 1.5mg) │
• │ • Window: Within 120 hours (5 days) │ │ • Window: Within 72 hours (up to 120h) │
• │ • Type: Progesterone receptor modulator │ │ • Type: High-dose progestin │
• │ • Efficacy: Superior to LNG across 5 d │ │ • Efficacy: ~85–90% (declines over time)│
• │ • BMI: Effective in BMI ≥30 kg/m² │ │ • BMI: Diminished in BMI ≥25–30 kg/m² │
• │ • Crucial Rule: PAUSE routine hormonal │ │ • Quick Start: Start/resume routine │
• │ contraception for 5 full days; barrier│ │ hormonal contraception IMMEDIATELY │
• │ backup for 14 days or until menses │ │ on same day; barrier backup for 7 d │
• │ • Requires prescription │ │ • Available over-the-counter (no ID/age)│
• └─────────────────────────────────────────┘ └─────────────────────────────────────────┘
• Clinical Pharmacology & Protocol Nuances
• 1. Copper T380A IUD

Efficacy : Greater than 99.9 % 99.9\% 99.9% efficacy when inserted within 120 hours (5 days) of unprotected intercourse. Represents the single most effective emergency contraceptive method.

Recent Guideline Update : Clinical trials have established that the 52-mg Levonorgestrel IUD (Mirena/Liletta) is non-inferior to the copper IUD when inserted within 5 days for emergency contraception, expanding patient choice for emergency LARC placement.

2. Oral Ulipristal Acetate (Ella, 30 mg)

Pharmacology : Selective progesterone receptor modulator (SPRM). It prevents or delays follicular rupture and ovulation.

Ovulatory Window Advantage : Unlike levonorgestrel, ulipristal acetate maintains the ability to inhibit ovulation even after the luteinizing hormone (LH) surge has already started , up until the immediate pre-ovulatory LH peak. Consequently, it demonstrates superior efficacy compared to levonorgestrel throughout the entire 120-hour (5-day) window.

Weight / BMI Performance : Ulipristal acetate retains high efficacy in patients who are overweight or obese (BMI ≥ 30 \ge 30 ≥ 30 kg/m²), whereas levonorgestrel efficacy declines markedly.

THE DRUG INTERACTION EXAM PEARL (The 5-Day Rule) : Because ulipristal binds competitively to progesterone receptors, administering exogenous progestins (such as initiating combined oral contraceptives, POPs, DMPA, or implants) immediately after ulipristal blunts ulipristal's emergency contraceptive efficacy and reduces the efficacy of the progestin. Therefore, patients who take ulipristal must WAIT at least 5 days before starting or restarting any hormonal contraceptive method. Furthermore, the patient must use a barrier method (condoms) for the 5-day waiting period PLUS an additional 7 to 14 days (total of 14 days or until their next menstrual period).

3. Oral Levonorgestrel (Plan B One-Step, 1.5 mg)

Pharmacology : Single 1.5 mg dose of high-dose levonorgestrel (or two 0.75 mg doses 12 hours apart). Acts strictly by blunting the LH surge before the LH rise has begun. If the LH surge is already underway or ovulation has occurred, levonorgestrel has zero clinical efficacy.

Timing : Labeled for administration within 72 hours (3 days) of unprotected intercourse, though it exhibits modest efficacy up to 120 hours (with progressive day-over-day efficacy decline).

Weight / BMI Limitations : Levonorgestrel demonstrates significantly reduced efficacy in women with a BMI ≥ 25 \ge 25 ≥ 25 kg/m² and is considered largely ineffective in individuals with a BMI ≥ 30 \ge 30 ≥ 30 kg/m². In overweight and obese patients, the copper IUD or ulipristal acetate is strongly preferred.

Same-Day Quick Start : Routine hormonal contraceptives can be started or resumed immediately on the same day following levonorgestrel intake. The patient must use barrier contraception for the subsequent 7 days .

Access : Available over-the-counter (OTC) to individuals of all genders and ages without a prescription, parental consent, or age verification.

Loading diagram... US MEC Contraceptive Safety & Emergency Contraception Selection Algorithm